» Articles » PMID: 31176297

Lean Non-alcoholic Fatty Liver Disease and Development of Diabetes: a Cohort Study

Overview
Specialty Endocrinology
Date 2019 Jun 9
PMID 31176297
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Non-alcoholic fatty liver disease (NAFLD), a condition associated with multiple metabolic abnormalities, is frequently observed in normal weight individuals (lean NAFLD). The metabolic consequences of lean NAFLD, however, are not well characterized. Thus, this study aimed to evaluate the risk of incident diabetes in lean NAFLD.

Methods: This is a cohort study of 51,463 adults without diabetes, history of liver disease or cancer at baseline who participated in a regular health screening exam. Fatty liver was diagnosed by ultrasonography. The study outcome was the development of diabetes during follow-up.

Results: During 236,446.6 person-years of follow-up (median follow-up of 4.0 years), 5370 participants developed diabetes. In fully adjusted models, the hazard ratios (HRs) for incident diabetes comparing lean participants with NAFLD, overweight/obese participants without NAFLD and overweight/obese participants with NAFLD to lean participants without NAFLD, were 1.18 (95% CI: 1.03-1.35), 1.06 (0.98-1.14) and 1.45 (1.34-1.57), respectively. The fully adjusted HR for incident diabetes for lean NAFLD participants with low NAFLD fibrosis score (NFS) (<-1.455) and with intermediate-to-high NFS (≥-1.455) compared to lean participants without NAFLD were 1.32 (1.14-1.53) and 2.73 (2.10-3.55), respectively.

Conclusions: In this large cohort study, the presence and severity of NAFLD in normal weight adults was associated with an increased incidence of diabetes independently of established risk factors. Indeed, isolated lean NAFLD was a stronger risk factor for incident diabetes than the presence of overweight/obesity without NAFLD. Subjects with lean NAFLD require careful monitoring for the development of metabolic abnormalities.

Citing Articles

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.

Danpanichkul P, Suparan K, Prasitsumrit V, Ahmed A, Wijarnpreecha K, Kim D Clin Mol Hepatol. 2024; 31(1):74-89.

PMID: 39439408 PMC: 11791619. DOI: 10.3350/cmh.2024.0631.


Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus.

Cheng Y, Wang S, Wang C, Kao J Tzu Chi Med J. 2024; 36(4):425-432.

PMID: 39421499 PMC: 11483085. DOI: 10.4103/tcmj.tcmj_253_23.


Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.

Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y BMC Med. 2024; 22(1):101.

PMID: 38448943 PMC: 10919055. DOI: 10.1186/s12916-024-03315-0.


Triglycerides Mediate the Influence of Body Mass Index on Non-Alcoholic Fatty Liver Disease in a Non-Obese Chinese Population with Normal Low-Density Lipoprotein Cholesterol Levels.

Han X, Kong J, Zhang H, Zhao Y, Zheng Y, Wei C Obes Facts. 2024; 17(2):191-200.

PMID: 38266508 PMC: 10987190. DOI: 10.1159/000536447.


Comparison of cardiometabolic risk factors between obese and non-obese patients with nonalcoholic fatty liver disease.

Yari Z, Fotros D, Hekmatdoost A Sci Rep. 2023; 13(1):14531.

PMID: 37666894 PMC: 10477254. DOI: 10.1038/s41598-023-41893-w.